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Prognostic Significance of the Number of Lymph Nodes
Removed at Lobectomy in Stage IA Non-small Cell
Lung Cancer
Sai-Hong Ignatius Ou, MD, PhD,*†‡ and Jason A. Zell, DO, MPH*†‡
Background: Lobectomy with mediastinal lymph node dissection is
the standard of care in stage IA non-small cell lung cancer
(NSCLC). We investigated whether the number of lymph nodes
removed influences survival in stage IA NSCLC patients who
underwent lobectomy.
Methods: 2545 stage IA NSCLC patients in the California Cancer
Registry who underwent lobectomy between 1999 and 2003 were
analyzed. Cox proportional hazards regression was used to identify
independent prognostic factors.
Results: Increasing number of lymph nodes removed was associated
with statistical significant improvements in overall survival (OS)
(p 0.0001) and lung cancer-specific survival (LCSS) (p 0.0309)
of stage IA NSCLC patients who underwent lobectomy. The number
of lymph nodes removed remained an independent favorable prog-
nostic factor for OS (ptrend  0.0001) and LCSS (ptrend  0.0095)
even after adjustment for other independent prognostic factors
including age, sex, histology, histologic grade, socioeconomic sta-
tus, and marital status in the Cox proportional regression analyses.
Removal of 11 to 15 lymph nodes conferred the lowest hazard ratio
for death [versus none; hazard ratio  0.52; 95% confidence
interval: 0.36–0.75].
Conclusions: The number of lymph nodes removed in stage IA
NSCLC patients who underwent lobectomy is an independent prog-
nostic factor for OS and LCSS.
Key Words: Stage IA NSCLC, Lobectomy, Number of lymph
nodes, Prognosis, Overall survival.
(J Thorac Oncol. 2008;3: 880–886)
Lung cancer is the number one cancer incidence in theworld and the number one cause of cancer mortality
worldwide.1 Even for early stage non-small cell lung cancer
(NSCLC), the 5 year survival is about 50 to 60%.2 Lobec-
tomy is the current standard curative treatment approach in
stage I NSCLC as lobectomy has been shown to confer
survival benefit over wedge resection/segmentectomy.3 After
curative resection, the current standard of care for stage I
NSCLC is surveillance as adjuvant chemotherapy or radiation
has not been shown to confer survival benefit in stage I
NSCLC.4 There is continual debate as to the extent of lymph
node dissection in stage I NSCLC as retrospective studies and
nonrandomized trials have shown that the higher the number
of lymph nodes removed at surgery or the more complete the
lymph node dissections for stage I NSCLC the better the
survival outcome,5–12 whereas results from head to head
randomized trials in early stage NSCLC were less clearly
defined.13–15 We have previously shown that tumor lobar
location is an independent prognostic factor for overall sur-
vival (OS) in stage IB but not stage IA NSCLC indicating
surgical techniques may play a role in survival of stage IB
NSCLC.16 In this report, we performed a population-based
retrospective analysis of the California Cancer Registry
(CCR) database to investigate whether the number of lymph
nodes removed in stage IA NSCLC patients who underwent
lobectomy is prognostic for OS and lung cancer-specific
survival (LCSS).
PATIENTS AND METHODS
Study Cohort and Diagnostic Codes
Data were obtained on 19,702 stage I NSCLC cases in
CCR from 1989 to 2003 with complete tumor, node, metas-
tasis (TNM) staging data and complete follow-up data as
previously described.16,17 Tumor site and histology were
abstracted as previously described.16,17 Only histologically or
cytologically confirmed NSCLC cases were included in the
analysis. Non-small cell histologies that were not coded as
adenocarcinoma, squamous cell carcinoma, large cell carci-
noma, bronchioloalveolar carcinoma, or as a metastatic lung
lesion from a separate primary tumor were categorized as
undifferentiated NSCLC as previously described.16,17 Ethnic-
ity, marital status, histologic grade, number of lymph nodes
removed, tumor lobe location, and tumor size were abstracted
using Surveillance, Epidemiology, and End Results (SEER)
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codes.16 The measurement of socioeconomic status (SES)
used in this analysis was a composite measure using CCR and
census data. Standardized component scores for the SES
index for the 20,919 census block groups were sorted and
categorized into quintiles, with a value of 1 representing the
lowest SES level and a value of 5 representing the highest
SES level.18 Radiation and surgical techniques (local treat-
ment, wedge/segmentectomy, lobectomy, and pneumonec-
tomy) were abstracted using SEER codes. Chemotherapy
given during the first course of therapy was ascertained using
CCR codes. The last date of follow-up was either the date of
death or the last date the patient was contacted.
The number of lymph nodes removed was obtained
using the CCR NNODES code. NNODES are number of
lymph nodes identified in the pathology report during surgical
procedure. Code 00 is no regional lymph nodes examined.
Code 01 is one regional lymph node examined. Codes 02 to
89 actual number of lymph nodes examined. Code 90 is 90 or
more lymph nodes examined. Codes 95 to 98 which included
categories where number of lymph nodes were unknown or
not stated in the pathology report or the lymph nodes re-
moved were not documented as part of surgical procedure are
grouped as not otherwise specified (NOS) in this manuscript.
Code 99 is coded as unknown/not stated/death certificate only
and is categorized as unknown in this manuscript. The num-
ber of lymph nodes removed was categorized into 6 groups:
0, 1 to 5, 6 to 10, 11 to 15, 15, NOS and unknown for
analysis purposes.
Statistical Analysis
Life-tables and Kaplan–Meier curves were generated
for OS and LCSS. Comparisons between groups were ana-
lyzed with the log-rank test. Multivariate Cox regression
analyses were used to determine factors significantly associ-
ated with survival. Statistical significance was assumed for a
two-tailed p value less than 0.05. All statistical analyses were
performed using SAS version 9.1 (SAS Institute, Cary, NC).
Ethical Considerations
This research study was approved by the University of
California Irvine Institutional Review Board (2004-3971 and
2007-6078).
RESULTS
Patient Characteristics and Numbers of Lymph
Nodes Removed
From 1989 to 2003, a total of 19,702 stage I NSCLC
patients were identified in CCR. A total of 3515 patients did
not receive any surgical intervention and an additional 130
patients lacking data on lymph node removal were excluded
from the analysis. Thus a total of 16,057 patients were
included in the initial data set. A total of 12,920 of these
patients (80.5%) received lobectomy, and 6127 of these
patients were stage IA. The number of lymph nodes removed
at surgery according to the periods of diagnosis (1989–1993,
1994–1996, 1999–2003) according to the total number of
stage I patients who underwent surgical resection, the total
number of stage I patients who underwent lobectomy, and the
total number of stage IA patients who underwent lobectomy
is listed in Table 1. The percentage of number of lymph nodes
removed but NOS decreased from 63.7% between 1989 and
1993 to 53.0% between 1994 and 1998 and further decreased
to only 8.4% between 1999 and 2003. There was a clear trend
that CCR was capturing the information on lymph nodes
removed in the most recent period of diagnosis (1999–2003)
more accurately. Therefore, we limited our final analysis to
the 2545 stage IA patients who underwent lobectomy and
were diagnosed between 1999 and 2003.
Patient Characteristics
The clinicopathologic characteristics of the 2545 pa-
tients grouped by the number of lymph nodes removed were
listed in Table 2. Of note there was no statistical significant
difference among the 5 tumor lobar locations and the distri-
bution of the number of lymph nodes removed.
Overall Survival Analysis
The 5-year and median OS for stage IA patients who
underwent lobectomy according to the number of lymph
nodes removed were 44.9% and 56 months respectively for
no lymph nodes removed, 57.9% and median OS not reached
TABLE 1. Relationship Between Period of Diagnosis and the
Number of Lymph Nodes Removed
Number of
LNs Removed
Period of Diagnosis
1989–1993 1994–1998 1999–2003
All stage I patients who underwent surgical treatment
N  2705 N  6868 N  6484
0 953 (35.2%) 2167 (31.6%) 1519 (23.4%)
1–5 14 (0.5%) 518 (7.5%) 2070 (31.9%)
6–10 7 (0.3%) 331 (4.8%) 1311 (20.2%)
11–15 3 (0.1%) 132 (1.9%) 575 (8.9%)
15 3 (0.1%) 111 (1.6%) 417 (6.4%)
NOS 1723 (63.7%) 3608 (52.5%) 542 (8.4%)
Unknown 2 (0.1%) 1 (0.01%) 50 (0.8%)
All stage I patients who underwent lobectomy
N  2173 N  5532 N  5215
0 575 (26.5%) 1300 (23.5%) 872 (16.7%)
1–5 11 (0.5%) 442 (8.0%) 1761 (33.8%)
6–10 6 (0.3%) 297 (5.4%) 1186 (227%)
11–15 3 (0.1%) 115 (2.1%) 510 (9.8%)
15 3 (0.1%) 90 (1.6%) 371 (7.1%)
NOS 1575 (72.5%) 3288 (59.4%) 482 (9.2%)
Unknown 0 (0.0%) 0 (0.0%) 33 (0.6%)
All stage IA patients who underwent lobectomy
N  924 N  2658 N  2545
0 250 (27.1%) 675 (25.4%) 455 (17.9%)
1–5 9 (1.0%) 218 (8.2%) 878 (34.5%)
6–10 3 (0.3%) 120 (4.5%) 569 (22.4%)
11–15 3 (0.3%) 56 (2.1%) 250 (9.8%)
15 0 (0.0) 34 (13.0%) 165 (6.5%)
NOS 659 (71.3%) 1555 (58.5%) 214 (8.4%)
Unknown 0 (0.0%) 0 (0.0%) 14 (0.6%)
LN, lymph nodes; NOS, no otherwise specified; N, number of patients.
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TABLE 2. Characteristics of Stage IA NSCLC Patients Who Received Lobectomy Grouped by Number of Lymph Nodes
Removed (1999–2003)
Total Number of Lymph Nodes Removed
0 1–5 6–10 11–15 >15 NOSa Unknown
N 455 878 569 250 165 214 14
Age
0–39 1 (0.2) 3 (0.3) 3 (0.5) 0 (0.0) 0 (0.0) 1 (0.5) 0 (0.0)
40–49 14 (3.1) 34 (3.9) 24 (4.2) 9 (3.6) 8 (4.9) 6 (2.8) 0 (0.0)
50–59 69 (15.2) 174 (19.9) 95 (16.7) 42 (16.8) 27 (16.4) 38 (17.8) 2 (14.9)
60–69 167 (36.7) 291 (33.1) 199 (35.0) 78 (31.2) 55 (33.3) 70 (32.8) 1 (7.4)
70–79 151 (33.2) 295 (33.6) 199 (35.0) 103 (41.2) 61 (37.0) 75 (35.0) 7 (50.0)
80–89 53 (11.6) 81 (9.2) 49 (8.6) 18 (7.2) 14 (8.5) 24 (11.2) 4 (28.6)
Ethnic origin
Caucasian 358 (78.7) 673 (76.7) 461 (81.0) 210 (84.0) 136 (82.4) 178 (83.2) 11 (78.6)
African American 21 (4.6) 69 (7.9) 25 (4.4) 14 (5.6) 11 (6.7) 10 (4.7) 0 (0.0)
Asian 39 (8.6) 78 (8.9) 43 (7.6) 14 (5.6) 7 (4.2) 14 (6.6) 1 (7.1)
Hispanic 35 (7.7) 58 (6.6) 39 (6.9) 11 (4.4) 11 (6.7) 11 (5.1) 2 (14.3)
Other 2 (0.4) 0 (0.0) 1 (0.2) 1 (0.4) 0 (0.0) 1 (0.6) 0 (0.0)
Sex
Male 256 (56.3) 476 (54.2) 335 (58.9) 137 (54.8) 88 (53.3) 136 (63.6) 11 (78.6)
Female 199 (43.7) 402 (45.8) 234 (41.1) 113 (45.2) 77 (46.7) 78 (36.5) 3 (21.4)
Socioeconomic
Quintile 1 (SES1–lowest) 60 (13.2) 93 (10.6) 62 (10.9) 22 (8.8) 14 (8.5) 22 (10.3) 1 (7.1)
Quintile 2 (SES2) 93 (20.4) 173 (19.7) 91 (16.0) 32 (12.8) 26 (15.8) 52 (24.3) 4 (28.6)
Quintile 3 (SES3) 110 (24.2) 216 (24.6) 119 (20.9) 56 (22.4) 37 (22.4) 46 (21.5) 4 (28.6)
Quintile 4 (SES4) 103 (22.6) 194 (22.1) 145 (25.5) 62 (24.8) 44 (26.7) 36 (16.8) 1 (7.1)
Quintile 5 (SES5–highest) 89 (19.6) 202 (23.0) 152 (26.7) 78 (31.2) 44 (26.7) 58 (27.1) 4 (28.6)
Marital status
Married 273 (60.0) 513 (58.4) 336 (59.1) 146 (58.4) 104 (63.0) 123 (57.5) 7 (50.0)
Unmarried 173 (38.0) 349 (39.8) 225 (39.5) 102 (40.8) 56 (33.9) 88 (41.1) 6 (42.9)
Unknown 9 (2.0) 16 (1.8) 8 (1.4) 2 (0.8) 5 (3.0) 3 (1.4) 1 (7.1)
Histology
Adenocarcinoma 222 (48.8) 443 (50.5) 284 (49.9) 113 (45.2) 83 (50.3) 87 (40.7) 7 (50.0)
Squamous cell carcinoma 81 (17.8) 174 (19.8) 107 (18.8) 63 (25.2) 25 (15.2) 58 (27.1) 2 (14.3)
Large cell carcinoma 21 (4.6) 31 (3.5) 19 (3.3) 12 (4.8) 5 (3.0) 8 (3.7) 0 (0.0)
BAC 79 (17.4) 160 (18.2) 121 (21.3) 44 (17.6) 42 (25.5) 40 (18.7) 4 (28.6)
Undifferentiated 52 (11.4) 70 (8.0) 38 (6.7) 18 (7.2) 10 (6.1) 21 (10.0) 1 (7.1)
Histologic grade
Well differentiated 84 (18.5) 137 (15.6) 99 (17.4) 40 (16.0) 34 (20.6) 28 (13.1) 3 (21.4)
Moderately differentiated 181 (39.8) 362 (41.2) 236 (41.5) 107 (42.8) 78 (47.3) 70 (32.7) 5 (35.7)
Poorly differentiated 126 (16.4) 281 (32.0) 172 (30.2) 76 (30.4) 39 (23.6) 72 (33.6) 3 (21.4)
Undifferentiated 15 (3.3) 26 (3.0) 10 (1.8) 10 (4.0) 3 (1.8) 7 (3.3) 0 (0.0)
Unknown 49 (10.8) 72 (8.2) 52 (9.1) 17 (6.8) 11 (6.7) 37 (15.4) 3 (21.4)
Tumor location
Right upper lobe (RUL) 183 (40.2) 366 (41.7) 211 (37.1) 90 (36.0) 66 (40.0) 79 (36.9) 8 (57.1)
Right middle lobe (RML) 37 (8.1) 50 (5.7) 24 (4.2) 12 (4.8) 7 (4.2) 11 (5.1) 0 (0.0)
Right lower lobe (RLL) 83 (18.2) 157 (17.9) 72 (12.7) 33 (13.2) 25 (15.2) 27 (12.6) 1 (7.1)
Left upper lobe (LUL) 104 (22.9) 191 (21.8) 177 (31.1) 75 (30.0) 46 (27.9) 64 (29.9) 2 (14.3)
Left lower lobe (LLL) 45 (9.9) 103 (11.7) 79 (13.9) 33 (13.2) 18 (10.9) 30 (14.0) 3 (21.4)
R  L main bronchus/carina/hilus 0 (0.0) 1 (0.1) 6 (1.1) 6 (2.4) 0 (0.0) 0 (0.0) 0 (0.0)
NOS 3 (0.7) 10 (1.1) 0 (0.0) 1 (0.4) 3 (1.8) 3 (1.4) 0 (0.0)
Radiation treatment
Yes 8 (1.8) 17 (1.9) 9 (1.6) 2 (0.8) 1 (0.6) 2 (0.9) 0 (0.0)
No 447 (98.2) 861 (98.1) 560 (98.4) 248 (99.2) 164 (99.4) 212 (99.1) 14 (100.0)
Chemotherapy
Yes 17 (3.7) 19 (2.2) 12 (2.1) 4 (1.6) 2 (1.2) 4 (1.9) 0 (0.0)
No 434 (95.4) 855 (97.4) 553 (97.2) 246 (98.4) 163 (98.8) 210 (98.1) 14 (100.0)
Unknown 4 (0.9) 4 (0.5) 4 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
a Not otherwise specified (lymph nodes removed but numbers unknown).
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(NR) respectively for 1 to 5 lymph nodes removed, 65.9%
and 67 months respectively for 6 to 10 lymph nodes removed,
68.2% and NR respectively for 11 to 15 lymph nodes re-
moved, 75.9% and 66 months respectively for 15 lymph
nodes removed, and 62.0% and NR respectively for numbers
of lymph nodes NOS removed. The difference in OS was
statistically significant (p  0.0001) (Figure 1).
The survival benefit of increasing number of lymph
nodes removed is also reflected in the multivariate analysis,
which included adjustment for age, sex, ethnicity, histology,
histologic grade, tumor lobar location, radiation, chemother-
apy, SES, and marital status (Table 3). The lowest hazard
ratio (HR) for death was between 11 and 15 lymph nodes
removed (versus none, HR  0.520; 95% confidence Inter-
val: 0.362–0.746). Other independent favorable prognostic
factors identified in the multivariate analysis included female
gender, well-differentiated histology, bronchioloalveolar car-
cinoma, and being married.
Cause of Death and LCSS in Stage IA NSCLC
Overall, 272 deaths occurred among the 2545 stage IA
NSCLC patients during the study period. Cause of death
analysis revealed that lung cancer was the most common
cause of the deaths (48.7%) suffered in this study. The 5-year
LCSS estimate were 75.4% for no lymph nodes removed,
79.5% for 1 to 5 lymph nodes removed, 85.4% for 6 to 10
lymph nodes removed, 83.7% for 11 to 15 lymph nodes
removed, 84.9% for 15 lymph nodes and 82.5% for lymph
nodes NOS removed (p  0.0309) (Figure 2). The number of
lymph nodes removed remained significant for LCSS in the
multivariate analysis where ptrend  0.0095.
DISCUSSION
This report demonstrates that the more lymph nodes
removed at time of lobectomy for stage IA NSCLC, the better
the survival outcomes. The univariate OS analysis indicates
that the best survival outcome was observed for patients with
more than 15 lymph nodes removed with an estimate 5-year
OS and LCSS of 75.9% and 84.9%, respectively. The sur-
vival advantage for increasing number of lymph nodes re-
FIGURE 1. Overall survival of stage IA NSCLC patients who
underwent lobectomy stratified by number of lymph nodes
removed.
TABLE 3. Cox Multivariate Model of Overall Survival for All
Stage IA Patients Who Underwent Lobectomy (n  2545)
HR
95% Confidence
Interval p
Ethnic origin
Caucasian 1.00
African American 0.895 (0.622–1.288) 0.5514
Hispanic 1.104 (0.777–1.568) 0.5804
Asian 0.781 (0.543–1.122) 0.1806
Other 0.960 (0.133–6.928) 0.9673
Age at diagnosisa 1.030 (1.020–1.040) 0.0001
Sex
Male 1.00
Female 0.638 (0.534–0.761) 0.0001
Marital status
Married 1.00
Unmarried 1.302 (1.088–1.559) 0.0040
Unknown 1.320 (0.714–2.440) 0.3758
SES
Quintile 1 (SES1–lowest) 1.00
Quintile 2 (SES2) 0.850 (0.629–1.148) 0.2895
Quintile 3 (SES3) 0.858 (0.641–1.149) 0.3040
Quintile 4 (SES4) 0.830 (0.614–1.122) 0.2256
Quintile 5 (SES5–highest) 0.868 (0.644–1.169) 0.3519
Histology
Adenocarcinoma 1.00
Squamous cell carcinoma 1.090 (0.885–1.343) 0.4176
Large cell carcinoma 0.810 (0.478–1.373) 0.4341
Bronchioloalveolar
carcinoma (BAC)
0.714 (0.534–0.956) 0.0234
Undifferentiated 0.892 (0.655–1.215) 0.4685
Location of Tumor
Left lower lobe (LLL) 1.00
Left upper lobe (LUL) 0.854 (0.641–1.139) 0.2832
Right upper lobe (RUL) 0.963 (0.736–1.260) 0.7851
Right middle lobe (RML) 1.226 (0.828–1.816) 0.3082
Right lower lobe (RLL) 0.885 (0.642–1.220) 0.4554
Number of lymph
nodes removedb
0 1.00
1–5 0.743 (0.578–0.956) 0.0208
6–10 0.535 (0.401–0.714) 0.0001
11–15 0.520 (0.362–0.746) 0.0004
15 0.605 (0.405–0.905) 0.0145
NOS 0.583 (0.409–0.833) 0.0030
Histologic grade
Well differentiated 1.00
Moderately differentiated 1.353 (1.008–1.815) 0.0442
Poorly differentiated 2.094 (1.551–2.826) 0.0001
Undifferentiated 1.719 (0.905–3.265) 0.0977
Unknown 1.300 (0.862–1.962) 0.2107
Radiation
No 1.00
Yes 1.373 (0.805–2.342) 0.2443
Chemotherapy
No 1.00
Yes 1.031 (0.615–1.727) 0.9089
Unknown 2.179 (0.802–5.918) 0.1266
a Analyzed as continuous variable.
b Unknown included in the Cox multivariate analysis but not shown.
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moved is likely primarily due to better and more accurate
staging of the underlying NSCLC. Even though lymph node
removal may also be therapeutic,19 for stage IA NSCLC the
therapeutic benefit is likely to be small since all lymph nodes
in stage IA were supposed to be negative. In addition,
although all the patients received lobectomy in this study, the
more extensive the lymph nodes dissection may reflect better
technical skills of the surgeons and the specialized care
provided by the treatment team.
The extent of lymphadenectomy in early stage NSCLC
has been controversial. Recent retrospective studies from
cancer registry,6 nonrandomized trials,7 and institutions8–13
have indicated that the number of resected lymph nodes is
associated with better OS8–11 and lung cancer specific sur-
vival9,10,12 in early stage NSCLC while the results from
randomized trials were less clearly defined. There are few
randomized clinical trials comparing lymph node sampling
versus lymphadenectomy in early stage NSCLC. Most ger-
mane to this report is the clinical trial by Sugi et al.13 where
115 patients with NSCLC less than 2 cm were randomized to
lobectomy with radical hilar and mediastinal lymph node
dissection versus lobectomy with mediastinal lymph node
sampling. There was no difference in the 5 year OS (81.4%
5-year survival estimate for dissection group versus 83.9%
for the sampling group). In a subgroup analysis of Izbicki et
al.14 systemic mediastinal lymphadenectomy did not improve
progression-free survival or OS in patients with N0 NSCLC
as compared with lymph node sampling. On the other hand,
in a subgroup analysis of a randomized trial conducted by Wu
et al.15 there was significant improvement in 5-year survival
of stage I NSCLC patients who underwent systemic nodal
dissection compared with mediastinal lymph node sampling
although the report did not further subdivide stage I into IA
and IB disease and almost twice as many stage I patient
received lymph node sampling than dissection.
We made several other observations in this report. First,
the proportion of patients with unknown number (not other-
wise specified) of lymph nodes removed has decreased dra-
matically between the period of 1993 and 1998 to the period
of 1999–2003 (i.e., from 53% to only about 8.4%, Table 1).
This likely reflects a combination of increased attention by
thoracic surgeons to label removed lymph nodes during
surgery, better effort by pathologists to count and examine
the lymph nodes removed, and the implementation of a new
EOD code by SEER in 1998 allowing better recording of the
number of lymph nodes removed by in the CCR. These
observations suggest that a continuous process of improve-
ment in these disparate fields (thoracic surgery, pathology,
cancer registry abstraction) and will lead to more accurate
lung cancer staging and prognostication. However, still
17.9% of lobectomy samples between 1999 and 2003 con-
tained no identified lymph node in the pathology report
indicating continual collaboration between surgeons and pa-
thologists is necessary to further optimize staging and prog-
nostication of these very early stage NSCLC patients. Cur-
rently there is no minimal recommended number of lymph
nodes that must be removed and examined to be considered
as complete nodal examination of the mediastinum whereas
in the staging of gastric cancer N3 is defined as 15 lymph
nodes involved implying at least 15 lymph nodes should be
examined to allow complete nodal staging. As reported in
colon,20,21 gastric,22 and pancreatic cancer,23 the more lymph
nodes resected and examined the better the survival outcome.
Greater than 15 lymph nodes removed in the present study
had the best OS by univariate analysis, while 11 to 15 lymph
nodes removed had the lowest HR in the multivariate analy-
sis. Thus the removal of more than 10 lymph nodes (10) as
suggested by Ludwig et al.6 and Doddoli et al.11 is consistent
with our epidemiologic observation. A third observation is
that there was no statistical difference in the number of lymph
nodes removed among the 5 major lobar locations. This is in
agreement with what we have previously reported that tumors
located in the upper lobar locations had a favorable survival
in stage IB but not stage IA patients.16 The final observation
is that despite the early stage of NSCLC in this study and
curative resection, close to 50% of the patients eventually
died of lung cancer. This implies that long term close sur-
veillance, better prognostication assays to stratify for adju-
vant chemotherapy treatment, and secondary chemopreven-
tion remain warranted for patients who have undergone
curative resection for early stage NSCLC.
There are several advantages of this study. First, we
analyzed only stage IA NSCLC patients who underwent
lobectomy which is the current and foreseeable future stan-
dard of care for this group of patients. The recent proposed
lung cancer staging changes retained the stage grouping of IA
disease, the same as current staging system.24 Thus, the
treatment for stage IA will not change because of the forth-
coming changes to the lung cancer staging system. Adjuvant
chemotherapy trials using molecular analysis to stratify stage
IA NSCLC into high and low risk groups are being conducted
but the results will not be available for many years.25 Second,
we analyzed data from the most recent time periods where the
data on the number of lymph nodes removed are more
accurate. In a previous analysis of SEER database, Ludwig et
al.6 did not mention the percentage of patients where the
number of lymph node removal was zero or NOS. Third, we
incorporated many prognostic factors into the Cox propor-
FIGURE 2. Lung cancer-specific survival of stage IA NSCLC
patients who underwent lobectomy stratified by number of
lymph nodes removed.
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tional hazards analyses including age, sex, ethnicity, histol-
ogy, histologic grade, SES, marital status, chemotherapy, and
radiation. We have previously demonstrated that poorly-
differentiated histology is an independent adverse prognostic
factor in stage IA in NSCLC.16 Kobayashi et al. also reported
that poorly-differentiated histology is the only poor prognos-
tic factor in stage IA NSCLC with tumor 2 cm or less.26 We
have also shown that SES and marital status are independent
prognostic factors in stage I NSCLC.27 Furthermore, we have
previously shown that untreated stage I NSCLC had a dismal
survival similar to stage IV NSCLC.28 Thus, the inclusion of
data on chemotherapy and radiation therapy use strengthens
our current analysis. We believe our finding is applicable to
general practice as the cancer registry data is from state-wide
clinical practice rather than limited to a single institution.
Disadvantages of this retrospective analysis are that
there is no standardized protocol for processing and exami-
nation of the lymph nodes removed, no standardized protocol
for staging of NSCLC, and we were unable to ascertain why
chemotherapy and/or radiation were given. In addition, the
number of patients who underwent mediastinoscopy was
unknown. It is conceivable that if pre-op mediastinoscopy
was negative, the number of lymph nodes removed may have
been reduced. Second, it was not possible to determine the
number of nodal stations resected or sampled. Since we only
analyzed stage IA NSCLC patients where any intrapulmo-
nary, hilar, or mediastinal lymph nodes examined should be
negative, it was impossible to identify the location and
number of nodal stations examined. Only when metastasis to
lymph nodes were identified were the lymph nodes involved
coded in the CCR and only then are we able to identify
whether N1, N2, or N3 nodes were involved from the coding
for N category. Thus, we can only assume that the more
lymph nodes examined, the more nodal stations and likely
mediastinal (N2) in addition to hilar/intrapulmonary (N1)
lymph nodes were examined. Indeed, Doddoli et al.11 has
shown that at least 2 nodal stations in addition to 10 lymph
nodes should be resected to be considered as complete resec-
tion.
This report contributes to the existing literature about
the need for extensive lymph node removal even in patients
who undergo curative surgical resection with the earliest
stage of NSCLC. Given that lobectomy remains the standard
of care in stage IA NSCLC patients, it is important to
optimize the survival outcome from lobectomy for these
patients. As shown by other retrospective studies12 and the
recent ACOSOG Z0030 randomized trial,29 the morbidity and
mortality are not increased with more extensive lymph node
dissection. And we eagerly await the final survival outcome
of ACOSOG Z0030 trial comparing mediastinal lymph node
sampling versus complete lymphadenectomy in early stage
NSCLC.
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